Oral ofloxacin therapy of Pseudomonas aeruginosa sepsis in mice after irradiation.
Death subsequent to whole-body irradiation is associated with gram-negative bacterial sepsis. The effect of oral therapy with the new quinolone ofloxacin for orally acquired Pseudomonas aeruginosa infection was tested in B6D2F1 mice exposed to 7.0 Gy of bilateral radiation from 60Co. A dose of 10(7) organisms was given orally 2 days after irradiation, and therapy was started 1 day later. Only 4 of 20 untreated mice (20%) survived for at least 30 days compared with 19 of 20 mice (95%) treated with ofloxacin (P less than 0.005). P. aeruginosa was isolated from the livers of 21 to 28 untreated mice (75%), compared with only 2 of 30 treated mice (P less than 0.005). Ofloxacin reduced colonization of the ileum by P. aeruginosa; 24 of 28 untreated mice (86%) harbored the organisms, compared with only 5 of 30 (17%) with ofloxacin (P less than 0.005). This experiment was replicated twice, and similar results were obtained. These data illustrate the efficacy of the quinolone ofloxacin for oral therapy of orally acquired P. aeruginosa infection in irradiated hosts.
Brook
I
I
Experimental Hematology Department, Armed Forces Radiobiology, Research Institute, Bethesda, Maryland 20814-5145.
Ledney
G D
GD
D000818:Animals; D003037:Cobalt Radioisotopes; D005260:Female; D007082:Ileum / Q000382:microbiology; D008099:Liver / Q000382:microbiology; D051379:Mice; D008815:Mice, Inbred Strains; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000097:blood / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology; D014916:Whole-Body Irradiation
D003037:Cobalt Radioisotopes; D015242:Ofloxacin